Spyre Therapeutics details 2026 shareholder votes
Spyre Therapeutics, Inc. reported results from its Annual Meeting of Stockholders held on May 27, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Spyre Therapeutics, Inc. reported results from its Annual Meeting of Stockholders held on May 27, 2026. Stockholders elected three Class I directors — Mark McKenna, Cameron Turtle and Laurie Stelzer — to serve until the 2029 annual meeting. They also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers and ratified KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026. In addition, stockholders approved the company’s amended and restated 2016 Employee Stock Purchase Plan, which provides a refreshed framework for employee share purchases. Effective the same day, director Peter Harwin resigned from the board, and the board size was reduced from eight to seven directors; his resignation was not due to any disagreement with the company.
8-K Event Classification
3 items: 5.02, 5.07, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Votes for Mark McKenna: 65,608,709 votes
Votes for Cameron Turtle: 66,176,245 votes
Votes for Laurie Stelzer: 56,954,664 votes
+4 more
7 metrics
Votes for Mark McKenna
65,608,709 votes
Election as Class I director at 2026 Annual Meeting
Votes for Cameron Turtle
66,176,245 votes
Election as Class I director at 2026 Annual Meeting
Votes for Laurie Stelzer
56,954,664 votes
Election as Class I director at 2026 Annual Meeting
Say-on-pay support
62,075,459 votes for
Non-binding advisory vote on executive compensation
Auditor ratification support
68,430,566 votes for
Ratification of KPMG LLP for year ending December 31, 2026
ESPP approval votes for
66,885,864 votes for
Approval of amended and restated 2016 Employee Stock Purchase Plan
Board size after resignation
7 directors
Board size reduced from eight effective May 27, 2026
Key Terms
Amended and Restated 2016 Employee Stock Purchase Plan, non-binding, advisory basis, independent registered public accounting firm, Broker Non-Votes, +1 more
5 terms
Amended and Restated 2016 Employee Stock Purchase Plan financial
"stockholders of the Company... approved the amended and restated 2016 Employee Stock Purchase Plan"
non-binding, advisory basis financial
"stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers"
A non-binding, advisory basis means a recommendation or decision that carries no legal force and does not obligate the parties to act; it’s similar to a friendly suggestion rather than a signed promise. For investors, this matters because such guidance can influence market expectations and management plans but offers no guarantee of follow-through, so investors should treat it as informative input rather than a firm commitment.
independent registered public accounting firm financial
"ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
Broker Non-Votes financial
"For | Against | Abstain | Broker Non-Votes 62,075,459 | 4,760,373 | 102,366 | 1,500,346"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
Annual Meeting of Stockholders financial
"at the Company’s Annual Meeting of Stockholders held on May 27, 2026"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Spyre Therapeutics (SYRE) stockholders approve at the 2026 annual meeting?
Stockholders approved the amended and restated 2016 Employee Stock Purchase Plan, endorsed executive compensation on a non-binding advisory basis, and ratified KPMG LLP as independent auditor for the year ending December 31, 2026, confirming the company’s compensation framework and audit arrangements.
Which directors were elected at Spyre Therapeutics (SYRE) 2026 annual meeting?
Three Class I directors were elected: Mark McKenna, Cameron Turtle and Laurie Stelzer. Each will serve until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified, maintaining continuity in Spyre Therapeutics’ board leadership structure.
How did Spyre Therapeutics (SYRE) stockholders vote on executive compensation?
Stockholders approved the compensation of the named executive officers on a non-binding, advisory basis, with 62,075,459 votes for, 4,760,373 against, and 102,366 abstentions, plus 1,500,346 broker non-votes, indicating broad support for the company’s executive pay program.
Who is Spyre Therapeutics’ (SYRE) auditor after the 2026 annual meeting vote?
KPMG LLP was ratified as Spyre Therapeutics’ independent registered public accounting firm for the year ending December 31, 2026, receiving 68,430,566 votes for, 670 against, and 7,308 abstentions, reflecting strong stockholder backing for the chosen auditor.
What happened to Spyre Therapeutics (SYRE) director Peter Harwin?
Effective May 27, 2026, Peter Harwin resigned from the board of Spyre Therapeutics. The company stated his resignation was not due to any disagreement regarding operations, policies, or practices, and the board size was reduced from eight directors to seven.
Was Spyre Therapeutics’ (SYRE) amended ESPP approved by stockholders?
Yes. The amended and restated 2016 Employee Stock Purchase Plan was approved with 66,885,864 votes for, 45,542 against, 6,792 abstentions, and 1,500,346 broker non-votes, authorizing continuation of the plan under updated terms for eligible employees.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates